TMDX TransMedics Group Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TMDX

Price (delayed)

$87

Market cap

$3.02B

P/E Ratio

19.59

Dividend/share

N/A

EPS

$4.44

Enterprise value

$3.39B

?
Relative Growth: Rel. Growth: 81
Relative Strength: Rel. Strength: 32
Relative Valuation: Rel. Valuation: 63
Relative Profitability: Rel. Profitability: 85
Highlights
TMDX's equity has surged by 63% year-on-year and by 4.9% since the previous quarter
The revenue has grown by 26% YoY and by 5% from the previous quarter
The net income has soared by 112% YoY but it fell by 12% QoQ
TransMedics Group's EPS has surged by 108% YoY but it has decreased by 12% QoQ
The company's debt has surged by 67% YoY
The quick ratio has contracted by 32% YoY and by 2.4% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.transmedics.com
Peers: OBIO OM

Key stats

What are the main financial stats of TMDX

TMDX stock price

How has the TransMedics Group stock price performed over time
Intraday
-1.21%
1 week
-0.64%
1 month
-8.2%
1 year
-27.82%
YTD
-28.48%
QTD
30.98%

Financial performance

How have TransMedics Group's revenue and profit performed over time
Revenue
$668.47M
Gross profit
$392.35M
Operating income
$81.61M
Net income
$151.7M
Gross margin
58.7%
Net margin
22.7%
The net income has soared by 112% YoY but it fell by 12% QoQ
The company's net margin has surged by 68% YoY but it fell by 16% QoQ
The revenue has grown by 26% YoY and by 5% from the previous quarter
TMDX's gross profit is up by 24% year-on-year and by 4.4% since the previous quarter

Price vs fundamentals

How does TMDX's price correlate with its fundamentals

Growth

What is TransMedics Group's growth rate over time

Valuation

What is TransMedics Group stock price valuation
TMDX P/E details
P/E
19.59
P/B
5.8
P/S
4.5
EV/EBIT
36.18
EV/EBITDA
25.59
EV/Sales
5.08
TransMedics Group's EPS has surged by 108% YoY but it has decreased by 12% QoQ
TMDX's P/E is 19% below its last 4 quarters average of 24.4
TMDX's equity has surged by 63% year-on-year and by 4.9% since the previous quarter
The stock's P/B is 55% less than its 5-year quarterly average of 13.0 and 24% less than its last 4 quarters average of 7.7
The P/S is 65% lower than the 5-year quarterly average of 12.9 and 19% lower than the last 4 quarters average of 5.6
The revenue has grown by 26% YoY and by 5% from the previous quarter

Efficiency

How efficient is TransMedics Group business performance
The ROA is up by 43% year-on-year but it is down by 22% since the previous quarter
The ROIC has contracted by 26% YoY and by 26% from the previous quarter
TransMedics Group's return on equity has decreased by 21% QoQ but it has increased by 18% YoY
TransMedics Group's return on sales has decreased by 17% QoQ and by 16% YoY

Dividends

What is TMDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TMDX.

Financial health

How did TransMedics Group financials performed over time
The total assets is 55% more than the total liabilities
The total liabilities has surged by 65% year-on-year
The total assets has soared by 64% YoY and by 2.1% from the previous quarter
The company's debt is 67% higher than its equity
The company's debt has surged by 67% YoY
TMDX's equity has surged by 63% year-on-year and by 4.9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.